Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAKER R DAKHIL

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1417918079
CMS profile
199929
Location
WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$105,533.44

397 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
McKesson Specialty Care Distribution, LLC $30,000.00 1
EISAI INC. $25,802.49 29
Celgene Corporation $10,750.44 13
Seattle Genetics, Inc. $8,116.12 19
Astellas Pharma Global Development $5,092.44 4
AbbVie Inc. $5,013.76 21
AMAG Pharmaceuticals, Inc. $4,958.08 10
Gilead Sciences, Inc. $4,022.47 8
Mylan Institutional Inc. $4,008.87 10
Halozyme Inc $900.00 1
Array BioPharma Inc. $771.96 5
AstraZeneca Pharmaceuticals LP $739.58 14
Genentech USA, Inc. $547.69 18
Novartis Pharmaceuticals Corporation $498.18 24
Merck Sharp & Dohme Corporation $416.23 28
PFIZER INC. $396.06 31
Janssen Biotech, Inc. $296.45 11
Amgen Inc. $279.18 20
E.R. Squibb & Sons, L.L.C. $264.76 21
Astellas Pharma US Inc $258.58 5
Taiho Oncology, Inc. $246.23 10
Takeda Pharmaceuticals U.S.A., Inc. $240.70 12
Bayer HealthCare Pharmaceuticals Inc. $209.14 10
Puma Biotechnology, Inc. $185.23 7
TESARO, Inc. $179.93 4
Verastem, Inc. $172.10 5
Clovis Oncology, Inc. $171.20 5
Incyte Corporation $146.51 4
TerSera Therapeutics LLC $109.04 5
Heron Therapeutics, Inc. $107.24 4
Exelixis Inc. $90.49 4
GENZYME CORPORATION $79.46 5
Pharmacyclics LLC, An AbbVie Company $67.75 5
Boehringer Ingelheim Pharmaceuticals, Inc. $55.18 3
Lilly USA, LLC $44.95 2
Rigel Pharmaceuticals, Inc. $41.54 2
Ipsen Biopharmaceuticals, Inc $38.78 2
Daiichi Sankyo Inc. $35.18 2
Regeneron Healthcare Solutions, Inc. $33.55 2
Sun Pharmaceutical Industries Inc. $28.42 2
Kyowa Kirin, Inc. $23.72 2
JAZZ PHARMACEUTICALS INC. $19.31 1
Blue Earth Diagnostics Limited $14.71 1
Helsinn Therapeutics (U.S.), Inc. $14.13 1
Servier Pharmaceuticals LLC $11.97 1
Alexion Pharmaceuticals, Inc. $11.80 1
Medtronic USA, Inc. $11.24 1
EMD Serono, Inc. $10.60 1

Page 8 of 8; records 351–397 of 397 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAKER R DAKHIL

NPI 1417918079 · CMS profile ID 199929

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 8; records 351–397 of 397 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–397 of 397 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 8; records 351–397 of 397 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
SHAKER R DAKHIL, NPI 1417918079, CMS profile ID 199929, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 8; records 351–397 of 397 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417918079?year=2019&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

397 matching records · $105,533.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 397 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–397 of 397.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $124.9702/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685939341 CMS
AbbVie, Inc. $6.7002/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647868063 CMS
Merck Sharp & Dohme Corporation $13.9202/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695282533 CMS
Bayer HealthCare Pharmaceuticals Inc. $10.4202/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628437803 CMS
GENZYME CORPORATION $19.5502/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693920149 CMS
PFIZER INC. $5.9202/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673119667 CMS
Janssen Biotech, Inc. $106.7802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658388585 CMS
Pharmacyclics LLC, An AbbVie Company $13.3602/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665700423 CMS
AMAG Pharmaceuticals, Inc. $10.2202/08/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 698512357 CMS
Merck Sharp & Dohme Corporation $8.7502/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695280237 CMS
Amgen Inc. $14.4502/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663035777 CMS
Genentech USA, Inc. $13.1902/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681236427 CMS
E.R. Squibb & Sons, L.L.C. $11.3902/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651319177 CMS
EISAI INC. $8.0502/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696998421 CMS
EISAI INC. $118.1802/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697035543 CMS
EISAI INC. $3,125.0002/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697035545 CMS
Ipsen Biopharmaceuticals, Inc $21.9602/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640619777 CMS
PFIZER INC. $6.7902/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673118847 CMS
Clovis Oncology, Inc. $11.0601/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688685167 CMS
Janssen Biotech, Inc. $7.2701/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658388577 CMS
Janssen Biotech, Inc. $89.1201/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658388571 CMS
PFIZER INC. $14.5101/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673118655 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.0101/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697385505 CMS
Taiho Oncology, Inc. $7.7401/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679412343 CMS
AstraZeneca Pharmaceuticals LP $12.4901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685243479 CMS
Astellas Pharma US Inc $19.8701/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655527177 CMS
AstraZeneca Pharmaceuticals LP $12.5001/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685117805 CMS
Seattle Genetics, Inc. $7.0001/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 678801069 CMS
EISAI INC. $13.1601/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696996257 CMS
Merck Sharp & Dohme Corporation $10.2101/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695247157 CMS
Array BioPharma Inc. $700.0001/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700973173 CMS
Genentech USA, Inc. $10.0801/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681236297 CMS
Taiho Oncology, Inc. $23.8801/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679412341 CMS
Amgen Inc. $1.8701/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663035775 CMS
Clovis Oncology, Inc. $13.3101/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688684735 CMS
Novartis Pharmaceuticals Corporation $16.7801/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659153927 CMS
Puma Biotechnology, Inc. $9.0901/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706018607 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.6701/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700449001 CMS
Amgen Inc. $18.2201/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663035829 CMS
Daiichi Sankyo Inc. $13.4801/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695395341 CMS
Puma Biotechnology, Inc. $9.0901/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706018601 CMS
Genentech USA, Inc. $3.7501/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681194342 CMS
Genentech USA, Inc. $3.5001/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681210597 CMS
Novartis Pharmaceuticals Corporation $22.7601/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659153921 CMS
AstraZeneca Pharmaceuticals LP $48.7101/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685922677 CMS
Ipsen Biopharmaceuticals, Inc $16.8201/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 640647169 CMS
Daiichi Sankyo Inc. $21.7001/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695290435 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $105,533.44 397
PY2020 $126,175.44 305
PY2021 $112,607.50 300
PY2022 $65,788.97 314
PY2023 $86,428.76 313
PY2024 $42,832.78 286
PY2025 $39,872.52 242

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $469.66 2
PY2025 Principal investigator $1,587,717.72 52
PY2024 Principal investigator $1,520,759.10 52
PY2023 Principal investigator $633,759.48 103
PY2022 Principal investigator $664,292.24 79
PY2021 Principal investigator $1,279,119.78 115
PY2020 Recipient $898.50 2
PY2020 Principal investigator $2,529,101.57 167
PY2019 Recipient $79,430.00 5
PY2019 Principal investigator $2,445,340.11 126

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $5,222.39 12/31/2025 Non-covered Recipient Entity
Cancer Center of Kansas
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 No dispute reported 06/30/2026 1232927907
Principal investigator 1 Amgen Inc. $3,500.00 12/23/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246639891
Principal investigator 1 BeOne Medicines Ltd. $5,639.00 12/23/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332177
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 12/09/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332179
Recipient Novartis Pharmaceuticals Corporation $332.54 12/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291284
Principal investigator 1 Amgen Inc. $38,476.00 11/25/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246649890
Principal investigator 1 BeOne Medicines Ltd. $1,282.00 11/12/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332283
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,395.56 11/11/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190298334
Principal investigator 1 Incyte Corporation $23,619.09 11/10/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512131
Principal investigator 1 Novartis Pharmaceuticals Corporation $214.02 10/28/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190298325
Principal investigator 1 Novartis Pharmaceuticals Corporation $151,514.98 10/27/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190298311
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $411.00 10/23/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS P.A.
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737859
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $248.00 10/23/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS P.A.
EMERGE 402: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca No dispute reported 06/30/2026 1233737861
Principal investigator 1 Amgen Inc. $95,594.72 09/24/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, HERITAGE PLAZA MEDICAL BUILDING
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312) No dispute reported 06/30/2026 1246639889
Principal investigator 1 PFIZER INC. $1,519.00 09/02/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228757713
Principal investigator 1 BeOne Medicines Ltd. $2,806.00 08/26/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332279
Principal investigator 1 BeOne Medicines Ltd. $2,025.00 08/12/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332175
Recipient Novartis Pharmaceuticals Corporation $137.12 08/05/2025 Covered Recipient Physician CABL001AUS08 No dispute reported 06/30/2026 1190293488
Principal investigator 1 BeOne Medicines Ltd. $3,769.00 07/22/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190332281
Principal investigator 1 Incyte Corporation $22.05 06/24/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512118
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $967.40 06/13/2025 Non-covered Recipient Entity
Cancer Center Of Kansas
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies No dispute reported 06/30/2026 1235998430
Principal investigator 1 Genentech, Inc. $1,750.05 06/09/2025 Non-covered Recipient Entity
MAYO CLINIC ROCHESTER REMIT PROCESSING
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211622922
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,515.48 06/05/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS PA
A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER No dispute reported 06/30/2026 1184204155
Principal investigator 1 BeiGene, Ltd. $2,499.00 05/20/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322622
Principal investigator 1 BeiGene, Ltd. $3,399.00 05/12/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325110
Principal investigator 1 PFIZER INC. $1,519.00 05/05/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228772190
Principal investigator 1 BeiGene, Ltd. $1,552.00 04/29/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325112
Principal investigator 1 BeiGene, Ltd. $2,025.00 04/29/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325114
Principal investigator 1 Mirati Therapeutics, Inc. $4,560.72 04/28/2025 Non-covered Recipient Entity
Cancer Center Of Kansas
A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Ther No dispute reported 06/30/2026 1236531209
Principal investigator 1 Merck Sharp & Dohme LLC $13,490.40 04/16/2025 Non-covered Recipient Entity
Cancer Center of Kansas
A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975 No dispute reported 06/30/2026 1232927905
Principal investigator 1 Incyte Corporation $3,889.06 04/15/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512123
Principal investigator 1 Hoffmann-La Roche Limited $16,515.50 04/10/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS PA
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1211583211
Principal investigator 1 BeiGene, Ltd. $1,716.00 04/08/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322620
Principal investigator 1 AstraZeneca UK Limited $8,341.43 04/02/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, PA
A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1185543638
Principal investigator 1 Novartis Pharmaceuticals Corporation $355,996.06 04/02/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) No dispute reported 06/30/2026 1190298330
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,921.00 03/27/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
Two arm Randomized Phase 3 study in high risk NSCLC comparing canakinumab vs placebo in Adjuvant Setting No dispute reported 06/30/2026 1190298319
Principal investigator 1 BeiGene, Ltd. $4,214.00 03/25/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322618
Principal investigator 1 Acerta Pharma LLC $848.20 03/19/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, PA
a randomized,multicenter,open label,3 arm phase 3 study of obinutuzumab in combination with chlorambucil,ACP 196 in combination with obinutuzumaband ACP 196 monotherapy in subjects with previously untreated chronic lymphocytic leukemia No dispute reported 06/30/2026 1185543634
Principal investigator 1 Acerta Pharma LLC $4,609.09 03/13/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS, PA
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185543632
Principal investigator 1 Hoffmann-La Roche Limited $13,395.60 03/13/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS PA
A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING ATEZOLIZUMAB ANTI PD L1 ANTIBODY No dispute reported 06/30/2026 1211583208
Principal investigator 1 ABBVIE INC. $13,000.00 03/07/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS P A
M22-128 - A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (EPCORE DLBCL-4) No dispute reported 06/30/2026 1202461402
Principal investigator 1 BeiGene, Ltd. $1,918.00 02/25/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322616
Principal investigator 1 PFIZER INC. $1,519.00 02/24/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228787799
Principal investigator 1 BeiGene, Ltd. $13,038.00 02/11/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322786
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,916.00 02/11/2025 Non-covered Recipient Entity
Translational Oncology Research International
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma(CheckMate 9ER: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9ER No dispute reported 06/30/2026 1235992897
Principal investigator 1 BeiGene, Ltd. $1,439.81 02/03/2025 Covered Recipient Teaching Hospital
Ronald Reagan Ucla
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325314
Principal investigator 1 Incyte Corporation $44.10 01/30/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240512113
Principal investigator 1 BeiGene, Ltd. $2,025.00 01/28/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320282
Principal investigator 1 BeiGene, Ltd. $4,414.00 01/28/2025 Non-covered Recipient Entity
Cancer Center of Kansas, P.A.
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320284
Principal investigator 1 Acerta Pharma LLC $5,331.00 01/23/2025 Non-covered Recipient Entity
TRANSLATIONAL ONCOLOGY RESEARCH INTERNATIONAL
A Randomized, Multicentre, Open-Label, Phase 3 Study to Compare Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with and without Obinutuzumab Compared to Investigator Choice of Chemoimmunotherapy in Subjects with Previously Untreated CLL Without del(17p) or TP53 Mutation No dispute reported 06/30/2026 1185543636
Principal investigator 1 Mirati Therapeutics, Inc. $21,185.00 01/15/2025 Non-covered Recipient Entity
Cancer Center Of Kansas
A Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation No dispute reported 06/30/2026 1236531205
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,809.56 01/09/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190298339
Principal investigator 1 Genentech, Inc. $1,000.00 01/08/2025 Non-covered Recipient Entity
TRANSLATIONAL RESEARCH IN ONCOLOGY US INC
Atezo or Pembro plus chemo with or without Tiragolumab in 1L NSCLC SKYSCRAPER 06 No dispute reported 06/30/2026 1211673720
Principal investigator 1 Novartis Pharmaceuticals Corporation $686,071.45 01/01/2025 Non-covered Recipient Entity
CANCER CENTER OF KANSAS
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190298316